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INTRODUCTION
B-type natriuretic peptide (BNP) has been isolated from
porcine brain, and shares remarkable sequence homology with
and has physiologic effects similar to atrial natriuretic peptide
(ANP) (1). Under conditions of sustained ventricular expan-
sion and volume overload, proBNP is released into blood,
where it is cleaved into BNP, the physiologically active hor-
mone, and an N-terminal fragment (NT-proBNP), an inac-
tive metabolite (2). Therefore, increased plasma concentra-
tions of proBNP, BNP and NT-proBNP are markers of left
ventricular systolic dysfunction since they are synthesized
and secreted primarily by the myocardium during a period
of increased work (3). More recently, plasma BNP concentra-
tions have been reported to be increased after acute myocar-
dial infarction (4) and in patients presenting with acute coro-
nary syndromes (5). 
Percutaneous transluminal coronary angioplasty (PTCA)
and coronary artery bypass grafting (CABG) are widely used
to treat ischemic heart disease; however, it has been report-
ed that these procedures can increase plasma BNP (6, 7). It
was reported that PTCA increases BNP levels mildly and
transiently, but that CABG with cardioplegic arrest causes
major tissue injury and persistently high hormonal levels (8).
Therefore, plasma BNP might act as a myocardial stress mar-
ker after the coronary artery reperfusion. However, little data
comparative information is available about NT-proBNP be-
havior immediately after coronary artery angioplasty or by-
pass without cardiopulmonary bypass (CPB). Thus this study
was undertaken to compare the effects of different reperfusion
methods on plasma NT-proBNP in patients with coronary
artery disease who received PTCA or off-pump coronary artery
bypass (OPCAB).
MATERIALS AND METHODS
Patient selection
From December 2003 to December 2004, all patients were
evaluated for functional angina class according to the Cana-
dian Classification, and for heart failure status according to
the New York Heart Association classification. All patients
received a pre-operative echocardiographic examination to
evaluate left ventricular systolic function, and all had one or
more compromised vessels with stenosis exceeding 70% of
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Changes in N-terminal Pro B-type Natriuretic Peptide Concentration:
Comparative Study of Percutaneous Transluminal Coronary Angioplasty
and Off-Pump Coronary Artery Bypass Graft
The goal of this study was to compare the effects of different reperfusion methods
on N-terminal B-type natriuretic peptide (NT-proBNP) in percutaneous transluminal
coronary angioplasty (PTCA) or off-pump coronary artery bypass (OPCAB) patients.
Fifty subjects were enrolled in the study, 32 patients received PTCA and 18 OPCAB.
An NT-proBNP measurement was performed before intervention and at 1, 3, and
7 days after the procedures. NT-proBNP levels were not significantly different before
intervention (PTCA group 297± ±147.3 vs. OPCAB group 235± ±167.8 pg/mL, p>
0.05). However, 1 day after the procedures, NT-proBNP levels were higher in the
OPCAB group (PTCA 375± ±256.4 vs. OPCAB 1,415± ±737.6 pg/mL, p<0.05), after
3 days NT-proBNP reached peak levels (PTCA 480± ±363.0 vs. OPCAB 2,119± ±
818.4 pg/mL, p<0.05), and levels were reduced after 7 days (PTCA 292± ±243.7 vs.
OPCAB 522± ±334.0 pg/mL, p>0.05). PTCA induced a mild and transient increase
in NT-proBNP concentration, but OPCAB caused sustained high NT-proBNP lev-
els during the 7 day postoperatively. However, differences between NT-proBNP
levels associated with these two modalities showed a tendency to decrease rapid-
ly postoperatively.
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the luminal diameter of a major coronary artery by selective
coronary angiography.
Patients were excluded if they fulfilled one or more follow-
ing criteria: 1) significant valvular heart disease; 2) previous
myocardial infarction or unstable angina; 3) acute or chronic
heart failure; 4) cardiomyopathy; 5) left ventricular aneurysm
or hypertrophy; 6) systolic dysfunction with an ejection frac-
tion of <45%; 7) perioperative myocardial infarction; and 8)
a renal or a hepatic pathology. The protocol used was approved
by our hospital’s ethics committee and all patients provided
written informed consent prior to participating in the study.
The subjects were 50 patients, 30 men and 20 women
(mean age 68.7±12.2, range 46 to 88 yr) with coronary
artery disease and underwent elective PTCA or OPCAB at
Korea University Medical Center. Thirty-two of the patients
were received PTCA and 18 OPCAB (Table 1). Mean patient
age was marginally higher in PTCA group than in OPCAB
group (p=NS), and the number of diseased coronary arteries
tended to be greater in the OPCAB group (p=NS). One ves-
sel disease was more common in the PTCA group and three
vessels disease in OPCAB group. No significant difference
was observed between the two groups in terms of combined
diseases, ejection fraction (EF), or myocardium status.
Measurement of NT-proBNP plasma levels
Blood samples for NT-proBNP measurements were taken
within 24 hr before and 1, 3, and 7 days after the procedures.
Blood (15 mL) samples were taken from an antecubital vein
and distributed in tubes containing ethylenediaminetetraace-
ticacid (EDTA). The specimens were then centrifuged for less
than 1 hr, and the plasma obtained was frozen at -80℃ until
analysis. NT-proBNP was measured using a double antibody
sandwich technique and electrochemiluminescence immu-
noassay (Elecsys proBNP, Roche Diagnostics, Mannheim,
Germany), the intra-assay coefficient of variation was <6%
at both normal and elevated levels. Normal subject reference
values are dependent on age and sex; mean values vary from
88 pg/mL in men under 50 yr of age to 334 pg/mL in women
between 50 and 65 yr of age (data from manufacturer).
Treatment of coronary disease
In the PTCA group, coronary balloon angioplasty and stent
implantation was performed in fasted patients using standard
techniques. In all PTCA patients sirolimus-eluting stents
(Cyper
�, Cordis, a Johnson & Johnson company, Roden, The
Netherlands) or paclitaxel-eluting stents (Taxus
�, Boston Sci-
entific Corporation, Galway, Ireland) were used. High-pres-
sure balloon inflation was used in order to avoid stent under-
expansion.
In the OPCAB group, anesthetic technique is predicated
upon the avoidance of high-dose narcotics and the use of short-
and intermediate-acting anesthetic agents. During the oper-
ation, continuous nitroglycerine and intermittent esmolol
infusion were used for ischemic prophlyaxis and slowing the
heart rate. During the cardiac manipulation, the decreased
pump function was managed by volume overloading and use
of Trendelenberg positioning. The left internal mammary
artery (IMA) was attached to the left anterior descending ar-
tery, and right IMA or saphenous vein grafts to other coronary
arteries as appropriate in all patients. Distal end anastomo-
sis was constructed with the help of an intracoronary shunt
(AXIUSTM, Guidant Co. Cardiac Surgery, CA, U.S.A.). Stabi-
lization of the target coronary artery was accomplished using
the Genzyme ImmobilizerTM system (Genzyme Corp., MA,
U.S.A.). 
Statistical analysis
The patients were divided in two groups according to the
reperfusion procedure used and groups were compared by
the Mann-Whitney test. Changes in the plasma levels of NT-
proBNP were investigated by a nonparametric repeated mea-
sure of analysis of variance (Friedman test) within a group
and by the Mann Whitney test across groups on the same
day; all values are expressed as means±S.D. Linear regression
analysis was used to assess the relation between NT-proBNP
levels and the various parameters. Statistical analyses were
performed using Statistica 6.0 (Statsoft Tulsa, OK, U.S.A.),
and pvalues of <0.05 were considered statistically significant.
RESULTS
The number of reperfused coronary arteries was significantly
PTCA OPCAB
No. of patient 32 18
Age (yr) 72.4±12.21 63.3±10.55  p=NS
Male/Female 19/13 11/7 p=NS
Diabetes 10 (31.3%) 6 (33.3%) p=NS
Hypertension 17 (53.1%) 9 (50.0%) p=NS
EF (%) 51.2±5.35 49.7±3.89 p=NS
CKMB (%) 6.7±8.44 6.5±6.10 p=NS
Myocardium
NSTEMI 15 (46.9%) 9 (50.0%) p=NS
Unstable angina 10 (31.2%) 6 (33.3%) p=NS
Stable angina 7 (21.9%) 3 (16.7%) p=NS
CAD
1 vessel 10 (31.3%) 2 (11.1%) p<0.05
2 vessels 15 (46.9%) 6 (33.3%) p=NS
3 vessels 7 (21.9%) 10 (55.6%) p<0.05
No. of diseased vessels 2.2±1.3 3.1±1.5 p=NS
Table 1. Clinical characteristics of the patients studied
CAD, coronary artery disease; CKMB, creatine kinase-MB; EF, ejection
fraction; NSTEMI, non ST elevation myocardial infarction; OPCAB, off
pump coronary artery bypass; PTCA, percutaneous transluminal coro-
nary angioplasty.18 H.K. Kim, H.J. Kim, J.W. Kim, et al.
greater in the OPCAB group (PTCA group 1.5±0.6 vs.
OPCAB group 3.2±1.3, p<0.05). No hospital mortality
occurred in either group.
NT-proBNP levels in the two groups were not significantly
different before intervention (PTCA group 297±147.3 pg/
mL vs. OPCAB group 235±167.8 pg/mL, p=NS). One day
after PTCA or OPCAB, NT-proBNP levels were higher in
the OPCAB group than in the PTCA group (PTCA group
375±256.4 pg/mL vs. OPCAB group 1,415±737.6 pg/
mL, p<0.05) and after 3 days, NT-proBNP concentrations
peaked in both groups and the difference between the two
had widened (PTCA group 480±363.0 pg/mL vs. OPCAB
group 2,119±818.4 pg/mL, p<0.05). However, a reducing
temporal trend of NT-proBNP values was observed in both
groups after 7 days and no significant difference was apparent
between the two groups (PTCA group 292±243.7 pg/mL
vs. OPCAB group 522±334.0 pg/mL, p=NS) (Fig. 1).
DISCUSSION
Cardiac natriuretic peptides are being used as diagnostic
and prognostic markers in a variety of cardiovascular condi-
tions, e.g., hypertension, congestive heart failure, and acute
coronary syndrome, because of their unique characteristics and
their role in cardiovascular physiology (9). Moreover, recent
reports have shown that BNP concentrations increase during
uncomplicated coronary angioplasty despite stable cardiac
filling pressures, and during nuclear stress testing in patients
with stable coronary heart disease (6). The underlying mech-
anism of elevated BNP secretion has been suggested to be
transient myocardial hypoxia induced by coronary artery oc-
clusion, which inevitably is introduced by such procedures.
Under these conditions BNP stimulation may be due to the
augmented regional wall stretch occurred by ischemic attacks
even in the absence of pump dysfunction (10), or the source
of BNP appears to be ischemic and necrotic tissue (6, 11).
In addition, many authors have presented evidence that
plasma BNP concentrations become acutely elevated after
conventional CABG and that this elevation reflects left ven-
tricular function (12-14).
Palazzuoli et al. reported that PTCA increases BNP levels
mildly and transiently, but that conventional CABG causes
major tissue injury and persistently high hormonal levels (8).
However, CPB in conventional CABG was found to cause
an increase in circulating catecholamines and endothelins,
and to augment oxidative stress, electrolyte imbalance and
coagulative cascade activation, and to increase inflammatory
molecule levels (15). These results suggest that the gene exp-
ression, metabolism, and biological activity of BNP may be
altered after extracorporeal circulation. Moreover, Bail et al.
reported that a postoperative peak BNP at 24 hr does not
reflect a state of acute perioperative heart failure or myocar-
dial damage (12).
In the present study we compared effects on NT-proBNP
concentration according to reperfusion methods (PTCA and
OPCAB) in patients with CAD without CPB. NT-proBNP
has the comparable clinical utility because of the longer half
life, lower intra-individual variation and better in vitro sta-
bility comparing to BNP (16). 
We found that NT-proBNP levels were higher in the OP-
CAB group than in the PTCA. Some authors have inferred
that events such as general anesthesia, cardiac herniation, sta-
bilizer compression, blood flow blockage, reperfusion injury,
and systemic inflammation can cause substantial stress (17,
18). In addition, OPCAB can cause direct myocardial manip-
ulation, fluid overload to meet blood loss and rather longer
operation time which can be stress to myocardium. 
In addition, we did not compare the OPCAB group with
non-cardiac surgical group. However, Tayama et al. said that
BNP may be associated with the right ventricular dysfunc-
tion noted after pneumonectomy, owing to the decrease in
the volume of the pulmonary vascular bed (19). Therefore,
it was inferred that the non-cardiac surgery without damag-
ing right ventricular function might not affect plasma BNP
concentration.
In our hospital, during OPCAB we used a temporary intra-
coronary shunt which resulted in reduced acute ischemia and
wall motion abnormalities, and maintained left ventricular
function comparing to the occlusion technique (20). Palaz-
zuoli et al. demonstrated lowering of the BNP levels after
90 days, but the difference between on-pump CABG and
PTCA groups was still significant (8). In the present study,
NT-proBNP level in OPCAB group was so rapidly decreased
that there was no difference between two groups in the 7 days
postoperatively. These results revealed that OPCAB leads to
sustained elevations of NT-proBNP relative to that observed
with PTCA, and in addition, cardiopulmonary bypass can
be a major factor to increase and keep the BNP level high
for longer postoperative period.
In conclusion, PTCA was found to induce a mild and tran-
�
N
T
-
p
r
o
B
N
P
 
l
e
v
e
l
s
 
(
p
g
/
m
L
)
3,000
2,500
2,000
1,500
1,000
500
0
Preoperative 1st day 3rd day 7th day
Time
PTCA
OPCAB
Fig. 1. Temporal trends shown by NT-proBNP levels.
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sient increase in NT-proBNP concentration, whereas OPCAB
induced sustained high hormonal levels during the 7 day post-
operative period, which does not mean that OPCAB damages
the myocardium more severely. In this study, we do not mea-
sure any other specific biochemical markers of myocardial
damage including creatinine kinase MB isoforms, troponin-
T, and myoglobin. Therefore, other specific cardiac markers
should be added for NT-proBNP to act as a myocardial stress
marker.
Because our study was based on a short time interval, we
did not evaluate the relations between temporal changes in
the levels of these hormones and long-term prognosis, or bet-
ween the overall impact of the procedure and mortality, for
which longitudinal studies are advisable in a larger group of
patients. The major limitation of this study is that relative-
ly small patients were included.
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